Two Sigma Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Two Sigma Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-34,500	Closed	-$3.99M	–	2710
2023 Q3	$3.99M	Sell	34,500 -291,600	-89%	-$31.3M	0.01%	846
2023 Q2	$33.5M	Buy	326,100 +46,300	+17%	+$4.88M	0.09%	218
2023 Q1	$30.5M	Buy	279,800 +121,500	+77%	+$13.4M	0.08%	240
2022 Q4	$18M	Sell	158,300 -218,600	-58%	-$18.2M	0.05%	370
2022 Q3	$23.3M	Buy	376,900 +364,400	+2,915%	+$25.5M	0.07%	287
2022 Q2	$997K	Buy	+12,500	New	+$1.18M	﹤0.01%	1595
2022 Q1	–	Sell	-11,100	Closed	-$1.2M	–	3025
2021 Q4	$1.2M	Buy	+11,100	New	+$1.21M	﹤0.01%	1467
2021 Q2	–	Sell	-62,600	Closed	-$5.76M	–	2831
2021 Q1	$5.76M	Sell	62,600 -440,900	-88%	-$37.2M	0.02%	797
2020 Q4	$36.8M	Buy	503,500 +37,600	+8%	+$2.79M	0.1%	218
2020 Q3	$36.2M	Buy	465,900 +75,898	+19%	+$5.22M	0.1%	194
2020 Q2	$21.7M	Buy	390,002 +17,373	+5%	+$743K	0.06%	305
2020 Q1	$11M	Sell	372,629 -445,500	-54%	-$15.1M	0.04%	452
2019 Q4	$29.6M	Buy	818,129 +1,500	+0.2%	+$46K	0.07%	302
2019 Q3	$22.2M	Sell	816,629 -259,500	-24%	-$6.71M	0.05%	343
2019 Q2	$25.9M	Buy	1,076,129 +4,400	+0.4%	+$112K	0.06%	337
2019 Q1	$28.3M	Sell	1,071,729 -15,400	-1%	-$365K	0.07%	324
2018 Q4	$21.2M	Buy	1,087,129 +544,100	+100%	+$10.7M	0.06%	362
2018 Q3	$10.6M	Buy	543,029 +181,300	+50%	+$3.45M	0.03%	563
2018 Q2	$5.99M	Buy	361,729 +193,800	+115%	+$2.96M	0.02%	779
2018 Q1	$2.38M	Buy	167,929 +121,900	+265%	+$1.8M	0.01%	1167
2017 Q4	$672K	Buy	+46,029	New	+$646K	﹤0.01%	1671
2017 Q2	–	Sell	-19,629	Closed	-$290K	–	2475
2017 Q1	$290K	Buy	+19,629	New	+$318K	﹤0.01%	2099
2016 Q1	–	Sell	-16,429	Closed	-$356K	–	2194
2015 Q4	$356K	Buy	+16,429	New	+$320K	﹤0.01%	1460
2015 Q2	–	Sell	-33,400	Closed	-$867K	–	2154
2015 Q1	$867K	Buy	+33,400	New	+$612K	0.01%	1136
2014 Q3	–	Sell	-18,200	Closed	-$288K	–	2811
2014 Q2	$288K	Buy	+18,200	New	+$260K	﹤0.01%	2035

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Two Sigma Advisers's HZNP Position: Q4 2023 in Review

Two Sigma Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 34,500 shares — an estimated $3.99M sold.

Two Sigma Advisers first reported a position in HZNP in Q2 2014 and held it in 25 quarters. The position peaked at $36.8M in Q4 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Two Sigma Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Two Sigma Advisers sold 34,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $3.99M.
Two Sigma Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 25 quarters.
Two Sigma Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $36.8M in Q4 2020.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Two Sigma Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.